Table 2.

Existing literature on Eltrombopag in poor graft function with or without isolated cytopenias after hematopoietic stem cell transplantation

References	No. of patients (n)	Patient population and characteristics	Median day of starting Eltrombopag	Median duration of treatment	Dose of Eltrombopag (mg)	Outcomes (%)	Comments/additional findings
Tang et al. [47]	12	PGF; ALL-4; AML-3; SAA-3	D + 175	8 weeks	25–50	83.3	66% sustained complete resolution after stopping drug
Milovic et al. [53]	4	PGF; AML-3; ALL-1	D + 83	NA	12.5–50	75	50% had sustained complete resolution; 1 patient had skin toxicity;
Giammarco et al. [54]	10	PGF + Isolated cytopenia; AML-4; ALL-3; MDS-2	D + 134	164 days	50–150	100	Patients also supported with G-CSF and EPO;
Marotta et al. [41]	12	PGF + PIT + SFPR; AML-5; ALL-1; MDS-2; SAA-1	D + 79	107 days	25–150	58.3	50% had sustained complete resolution; All patients MAC; 75% Haplo-identical patients
Fu et al. [48]	38	PGF + PIT + SFPR; AML-14; ALL-17; MDS-1; SAA-6	D + 179	64 days	25–50	63.2	Adequate megs prior to treatment favours response

PGF poor graft function, NA not available, ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, MDS myelodysplastic syndrome, SAA severe aplastic anemia, G-CSF granulocyte colony stimulating factor, EPO erythropoietin, MAC myeloablative conditioning, PIT persistent isolated thrombocytopenia, SFPR secondary failure of platelet recovery, megs megakaryocytes, EBMT European group of blood and marrow transplantation